Is Immuneering Corp halal to invest in?

According to Musaffa's Shariah screening methodology, Immuneering Corp (IMRX) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Immuneering Corp a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Immuneering Corp using these criteria to determine its compliance status.

Can Muslims buy shares of Immuneering Corp?

Muslim investors may consider investing in Immuneering Corp if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Immuneering Corp classified as NOT HALAL?

Musaffa determines the Shariah status of Immuneering Corp by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Immuneering Corp updated?

The Shariah compliance status of Immuneering Corp may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Immuneering Corp become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Immuneering Corp?

You can check the latest Shariah compliance status of Immuneering Corp on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

IMRX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 09, 2026

Report Source: 2025 Annual Report

Immuneering Corp. Stock Analysis IMRX

United States Health Care Small Cap Report: 2025 Annual

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2021-07-30. The firm is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

Key Statistics of Immuneering Corp (IMRX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$5.03$5.25

Today's Open

$5.10

Volume

650.99K

P/E Ratio (TTM)

52 Week Range

$1.22$10.08

Market Cap

345.25M

Avg. Volume

755.74K

Dividend Yield

Financial Metrics & Statements of Immuneering Corp (IMRX)

FAQ's for Immuneering Corp (IMRX)

According to Musaffa’s Shariah screening methodology, Immuneering Corp (IMRX) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.